Tyra Biosciences Unveils Early Data for FGFR3 Inhibitor, TYRA-300, in Challenge to J&J’s Balversa

Tyra Biosciences, TYRA-300, Balversa, J&J, bladder cancer, urothelial carcinoma, FGFR3 inhibitor, safety concerns, efficacy data

Vertex’s Non-Opioid Pain Drug Suzetrigine Nears FDA Approval: A Breakthrough in Acute Pain Management

Suzetrigine, Non-opioid pain drug, Acute pain management, FDA approval, Vertex Pharmaceuticals, NaV1.8 pain signal inhibitor, Opioid epidemic, Pain relief without addiction risk

Comparative Efficacy of J&J’s Erleada and Astellas/Pfizer’s Xtandi in Non-Metastatic Prostate Cancer: Real-World Study Insights

Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC), Erleada (Apalutamide), Xtandi (Enzalutamide), Real-World Study, Comparative Efficacy, Safety Profiles